PODD250117P250000
- 0.83
- 0.000.00%
Insulet Newsroom
Those Who Invested in Insulet (NASDAQ:PODD) Five Years Ago Are up 44%
Beta Bionics Sets Terms for Upsized $113M IPO
Insulet(PODD.US) Officer Sells US$3.47 Million in Common Stock
$Insulet(PODD.US)$ Officer Benjamin Eric sold 12,394 shares of common stock on Jan 21, 2025 at an average price of $280 for a total value of $3.47 million.Source: Announcement What is statement of
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Citi Maintains Insulet(PODD.US) With Buy Rating
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $315
Analysts Conflicted on These Healthcare Names: Elevance Health (ELV), Agilent (A) and Insulet (PODD)
Insulet To Present At J.P. Morgan 43rd Annual Healthcare Conference; Webcast At 6:45 PM ET
Insulet Launches Omnipod 5 In Five More Countries In Italy, Denmark, Finland, Norway And Sweden
Insulet Launches Revolutionary Omnipod 5 in Five More Countries in Europe
We Think Insulet (NASDAQ:PODD) Can Stay On Top Of Its Debt
Press Release: Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Bernstein Adjusts Price Target on Insulet to $315 From $305, Keeps Outperform Rating
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $315
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $305
Diabetes Device Maker Beta Bionics Files for $100M IPO
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
BofA Securities Maintains Insulet(PODD.US) With Buy Rating, Announces Target Price $305
High Quality Cyclical Stocks According to Morgan Stanley
Express News | Insulet Corp : UBS Raises Target Price to $280 From $253